PT  - JOURNAL ARTICLE
AU  - Hu, Mao
AU  - Shoaibi, Azadeh
AU  - Feng, Yuhui
AU  - Lloyd, Patricia C.
AU  - Wong, Hui Lee
AU  - Smith, Elizabeth R.
AU  - Amend, Kandace L.
AU  - Kline, Annemarie
AU  - Beachler, Daniel C.
AU  - Gruber, Joann F.
AU  - Mitra, Mahasweta
AU  - Seeger, John D.
AU  - Harris, Charlalynn
AU  - Secora, Alex
AU  - Obidi, Joyce
AU  - Wang, Jing
AU  - Song, Jennifer
AU  - McMahill-Walraven, Cheryl N.
AU  - Reich, Christian
AU  - McEvoy, Rowan
AU  - Do, Rose
AU  - Chillarige, Yoganand
AU  - Clifford, Robin
AU  - Cooper, Danielle D
AU  - Forshee, Richard
AU  - Anderson, Steven A.
TI  - Safety of Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years
AID  - 10.1101/2023.10.13.23296903
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.13.23296903
4099  - http://medrxiv.org/content/early/2023/10/15/2023.10.13.23296903.short
4100  - http://medrxiv.org/content/early/2023/10/15/2023.10.13.23296903.full
AB  - Importance Active monitoring of health outcomes after COVID-19 vaccination provides early detection of rare outcomes that may not be identified in prelicensure trials.Objective To conduct near real-time monitoring of health outcomes following COVID-19 vaccination in the United States (US) pediatric population aged 6 months to 17 years.Design We evaluated 21 pre-specified health outcomes; 15 were sequentially tested through near real-time surveillance, and 6 were monitored descriptively within a cohort of vaccinated children. We tested for increased rate of each outcome following vaccination compared to a historical comparator cohort.Setting This population-based study was conducted under the US Food and Drug Administration public health surveillance mandate using three commercial claims databases.Participants Children aged 6 months to 17 years were included if they received a monovalent COVID-19 vaccine dose before early 2023 and had continuous enrollment in a medical health insurance plan from the start of an outcome-specific clean window to the COVID-19 vaccination dose.Exposure Exposure was defined as receipt of a monovalent BNT162b2, mRNA-1273, or NVX-CoV2373 COVID-19 vaccine dose. The primary analysis evaluated dose 1 and dose 2 combined, and secondary analyses evaluated each dose separately. Follow-up time was censored at death, disenrollment, end of risk window, end of study period, or a subsequent dose administration.Main Outcomes Twenty-one prespecified health outcomes.Results The study included 4,102,016 enrollees aged 6 months to17 years. Thirteen of 15 outcomes sequentially tested did not meet the threshold for a statistical signal. In the primary analysis, myocarditis or pericarditis signals were detected following BNT162b2 vaccine in children aged 12-17 years old and seizures/convulsions signals were detected following vaccination with BNT162b2 and mRNA-1273 in children aged 2-4/5 years. However, in a post-hoc sensitivity analysis, the seizures/convulsions signal was sensitive to background rates selection and was not observed when 2022 background rates were selected instead of 2020 rates.Conclusions and Relevance Of the two signaled outcomes, the myocarditis or pericarditis signals are consistent with previously published reports. The new signal detected for seizures/convulsions among younger children should be further investigated in a robust epidemiological study with better confounding adjustment.Competing Interest StatementAnnemarie Kline, Cheryl McMahill-Walraven, Djeneba Audrey Djibo worked on grants, subcontracts, or contracts from Harvard Pilgrim Health Care Institute, Brown University (National Institute on Aging/ IMPACT Collaboratory), Reagan Udall Foundation for the FDA, Academy of Managed Care pharmacy's Biologics and Biosimilar Collective Intelligence Consortium (BBCIC), TherapeuticsMD, Reachnet (Louisiana Public Health Institute), IQVIA, Pfizer, Carelon Research (formerly Healthcore), and Patient Centered Outcomes Research Institute as employees of CVS Health and report stock or stock options from CVS Health; Carelon Research; Kandace Amend, Robin Clifford, John Seeger, and Jennifer Song reports stock or stock options in UnitedHealth Group; Daniel C. Beachler is an employee of Carelon Research who has previously contracted with Pfizer Inc. for separate projects. No other authors report relevant disclosures.Clinical Protocols https://bestinitiative.org/wp-content/uploads/2022/12/C19-Active-Monitoring-Protocol-Addendum-2022.pdf Funding StatementThe US Food and Drug Administration provided funding for this study and contributed as follows: led the design of the study, interpretation of the results, writing of the manuscript, decision to submit, and made contributions to the coordination of data collection and analysis of the data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We conducted this study within the Biologics Effectiveness and Safety (BEST) Initiative. FDA Amendments Act of 2007 required that FDA develop a national electronic system for monitoring safety of FDA-regulated medical products. FDA built the Sentinel Initiative in response to the congressional requirement, and the BEST Initiative commenced as a Center for Biologics Evaluation and Research (CBER) component of Sentinel. The Office of Human Research Protection (OHRP) determined that the regulations OHRP administers (45 CFR part 46) do not apply to the activities that are included in the FDA's Sentinel Initiative.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe study protocol was publicly posted previously and a brief report was published describing the preliminary results of BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years on JAMA Pediatrics, as referenced in the manuscript. Data analyses and related documents can be made available where needed, by contacting the corresponding author. De-identified participant data will not be shared without approval from the data partners. https://covid.cdc.gov/covid-data-tracker